

# Celine Verstuyft

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6479293/publications.pdf>

Version: 2024-02-01

124  
papers

6,125  
citations

116194

36  
h-index

81351

76  
g-index

139  
all docs

139  
docs citations

139  
times ranked

9371  
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma acetyl-carnitine and carnitine in major depressive episodes: a case-control study before and after treatment. <i>Psychological Medicine</i> , 2023, 53, 2307-2316.	2.7	5
2	The olfactory deficits of depressed patients are restored after remission with venlafaxine treatment. <i>Psychological Medicine</i> , 2022, 52, 2062-2070.	2.7	7
3	Nitric Oxide Synthase activity in major depressive episodes before and after antidepressant treatment: Results of a large case-control treatment study. <i>Psychological Medicine</i> , 2022, 52, 80-89.	2.7	11
4	Galaxy Is a Suitable Bioinformatics Platform for the Molecular Diagnosis of Human Genetic Disorders Using High-Throughput Sequencing Data Analysis: Five Years of Experience in a Clinical Laboratory. <i>Clinical Chemistry</i> , 2022, 68, 313-321.	1.5	7
5	The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort. <i>Journal of Affective Disorders</i> , 2022, 299, 335-343.	2.0	0
6	Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. <i>Lancet Rheumatology</i> , The, 2022, 4, e24-e32.	2.2	34
7	Exome sequencing allows detection of relevant pharmacogenetic variants in epileptic patients. <i>Pharmacogenomics Journal</i> , 2022, , .	0.9	1
8	Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review. <i>Pharmaceuticals</i> , 2022, 15, 749.	1.7	3
9	REPLY:. <i>Hepatology</i> , 2021, 73, 2616-2616.	3.6	0
10	Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia. <i>JAMA Internal Medicine</i> , 2021, 181, 32.	2.6	654
11	Evaluating 10 Commercially Available SARS-CoV-2 Rapid Serological Tests by Use of the STARD (Standards for Reporting of Diagnostic Accuracy Studies) Method. <i>Journal of Clinical Microbiology</i> , 2021, 59, .	1.8	23
12	Hypoglycemia and Glycemic Control With Glyburide in Women With Gestational Diabetes and Genetic Variants of Cytochrome P450 2C9 and/or OATP1B3. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 141-148.	2.3	5
13	Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 295-304.	5.2	232
14	Blood microbiota and metabolomic signature of major depression before and after antidepressant treatment: a prospective case-control study. <i>Journal of Psychiatry and Neuroscience</i> , 2021, 46, E358-E368.	1.4	21
15	The Olfactory Deficits of Depressed Patients are Restored After Remission With Venlafaxine Treatment. <i>Biological Psychiatry</i> , 2021, 89, S160.	0.7	3
16	Population pharmacokinetic model of blood THC and its metabolites in chronic and occasional cannabis users and relationship with on-site oral fluid testing. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3139-3149.	1.1	9
17	Peripheral tryptophan and serotonin and kynurenine pathways in major depression: A case-control study. <i>European Psychiatry</i> , 2021, 64, S328-S328.	0.1	0
18	Peripheral tryptophan, serotonin, kynurenine, and their metabolites in major depression: A case-control study. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 112-117.	1.0	47

#	ARTICLE	IF	CITATIONS
19	Post-Liver Transplantation Sinusoidal Obstruction Syndrome With Refractory Ascites Induced by Mycophenolate Mofetil. <i>Hepatology</i> , 2020, 71, 1508-1510.	3.6	11
20	SOD2 genetic polymorphism (rs4880) has no impact on 6-month response to antidepressant treatment and inflammatory biomarkers in depressed patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 289-295.	1.2	5
21	Lower plasma vascular endothelial growth factor A in major depressive disorder not normalized after antidepressant treatment: A case control study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 402-408.	1.3	3
22	Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study. <i>Drugs in R and D</i> , 2020, 20, 331-342.	1.1	5
23	Transplacental transfer of glyburide in women with gestational diabetes and neonatal hypoglycemia risk. <i>PLoS ONE</i> , 2020, 15, e0232002.	1.1	5
24	Association between rs4149056 variant in SLCO1B1 and early discontinuation of statin after acute myocardial infarction. <i>Pharmacogenomics</i> , 2020, 21, 163-172.	0.6	3
25	Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1250-1258.	1.3	6
26	Naltrexone Use in Treating Hypersexuality Induced by Dopamine Replacement Therapy: Impact of OPRM1 A/G Polymorphism on Its Effectiveness. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3002.	1.8	13
27	Human Dermal Fibroblast: A Promising Cellular Model to Study Biological Mechanisms of Major Depression and Antidepressant Drug Response. <i>Current Neuropharmacology</i> , 2020, 18, 301-318.	1.4	7
28	Psychiatric Side Effects of Chloroquine. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	4
29	S80. The TRKB rs2289656 Genetic Polymorphism is Associated With Acute Suicide Attempts in Depressed Patients: A Transversal Case Control Study. <i>Biological Psychiatry</i> , 2019, 85, S328.	0.7	0
30	FRI-083-Impact of acetaminophen on acute liver failure of unknown cause. <i>Journal of Hepatology</i> , 2019, 70, e421.	1.8	0
31	Secondary actionable findings identified by exome sequencing: expected impact on the organisation of care from the study of 700 consecutive tests. <i>European Journal of Human Genetics</i> , 2019, 27, 1197-1214.	1.4	18
32	Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1538-1543.	1.1	16
33	P.009 The peripheral serotonin pathway in major depression before and after antidepressant treatment: a case-control prospective study. <i>European Neuropsychopharmacology</i> , 2019, 29, S26.	0.3	0
34	HOMA-IR increase after antidepressant treatment in depressed patients with the Met allele of the Val66Met BDNF genetic polymorphism. <i>Psychological Medicine</i> , 2019, 49, 2364-2369.	2.7	2
35	Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation. <i>Clinical Pharmacokinetics</i> , 2019, 58, 593-613.	1.6	37
36	Methemoglobinemia as a biomarker of dapsone-induced mania severity. <i>Journal of Affective Disorders</i> , 2019, 254, 122-123.	2.0	1

#	ARTICLE	IF	CITATIONS
37	Framingham coronary score in individuals with symptoms or diagnoses of mental disorders: A review and meta-analysis. <i>Psychiatry Research</i> , 2018, 263, 41-47.	1.7	5
38	Possible role of <i>CYP2B6</i> genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 337-342.	1.0	10
39	The association of <i>Î2-arrestin2</i> polymorphisms with response to antidepressant treatment in depressed patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 74-79.	2.5	8
40	Restless Legs Syndrome and Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 91-92.	0.7	3
41	Differential pharmacokinetic interaction of cyclosporine and tacrolimus with colchicine in renal allograft recipients. <i>Clinical Transplantation</i> , 2018, 32, e13405.	0.8	3
42	The <i>TRKB</i> rs2289656 genetic polymorphism is associated with acute suicide attempts in depressed patients: A transversal case control study. <i>PLoS ONE</i> , 2018, 13, e0205648.	1.1	7
43	Pharmacoresistant Severe Mental Health Disorders in Children and Adolescents: Functional Abnormalities of Cytochrome P450 2D6. <i>Frontiers in Psychiatry</i> , 2018, 9, 2.	1.3	27
44	Early weight gain predicts later weight gain in depressed patients treated with antidepressants: Findings from the METADAP cohort. <i>Journal of Affective Disorders</i> , 2018, 241, 22-28.	2.0	5
45	Frequency of tumour necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1835-1836.	0.5	7
46	Glycogen synthase kinase-3 $\beta$ genetic polymorphisms and insomnia in depressed patients: A prospective study. <i>Journal of Affective Disorders</i> , 2018, 240, 230-236.	2.0	11
47	Early weight gain predicts later metabolic syndrome in depressed patients treated with antidepressants: Findings from the METADAP cohort. <i>Journal of Psychiatric Research</i> , 2018, 107, 120-127.	1.5	8
48	Pioglitazone could induce remission in major depression: a meta-analysis. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 9-16.	1.0	58
49	No impact of eight <i>NTRK2</i> genetic polymorphisms on 6-month antidepressant efficacy in depressed patients. <i>Pharmacogenomics</i> , 2017, 18, 349-357.	0.6	2
50	Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation " recommendations from the French National Network of Pharmacogenetics. <i>Therapie</i> , 2017, 72, 311-318.	0.6	17
51	Should a routine genotyping of <i>CYP2D6</i> and <i>CYP2C19</i> genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?. <i>Pharmacogenomics</i> , 2017, 18, 639-650.	0.6	19
52	The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 435-441.	1.2	11
53	Editorial. <i>Therapie</i> , 2017, 72, 173-174.	0.6	0
54	Severe insomnia is associated with hypertriglyceridemia in women with major depression treated in psychiatry settings. <i>Journal of Affective Disorders</i> , 2017, 217, 159-162.	2.0	7

#	ARTICLE	IF	CITATIONS
55	PPAR- $\beta$ Agonists for the Treatment of Major Depression: A Review. <i>Pharmacopsychiatry</i> , 2017, 50, 49-55.	1.7	67
56	Genetics of Nevirapine Metabolic Pathways at Steady State in HIV-Infected Cambodians. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	3
57	Plasma BDNF Level in Major Depression: Biomarker of the Val66Met BDNF Polymorphism and of the Clinical Course in Met Carrier Patients. <i>Neuropsychobiology</i> , 2017, 75, 39-45.	0.9	22
58	Single-center, single-dose, open-label, randomized, two-period crossover study on the bioavailability of methotrexate administered using a novel prefilled, needle-free delivery system. <i>Current Medical Research and Opinion</i> , 2017, 33, 605-611.	0.9	4
59	GSK-3 $\beta$ rs334558 is associated with severe insomnia in patients with major depressive episode, but not with remission after antidepressant treatment. <i>European Neuropsychopharmacology</i> , 2017, 27, S793-S794.	0.3	0
60	FR10180...Multiple sclerosis risk-alleles study in patients with demyelinating side effects on anti tnf alpha therapy. , 2017, , .		0
61	Importance of therapeutic drug monitoring associated with pharmacogenetics: case reports in a French psychiatric hospital. <i>European Neuropsychopharmacology</i> , 2016, 26, S585-S586.	0.3	0
62	Tobacco use is associated with increased plasma BDNF levels in depressed patients. <i>Psychiatry Research</i> , 2016, 246, 370-372.	1.7	16
63	Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach. <i>Neuropharmacology</i> , 2016, 105, 142-153.	2.0	32
64	Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide. <i>PLoS ONE</i> , 2016, 11, e0151696.	1.1	13
65	Liver Function Test Abnormalities in Depressed Patients Treated with Antidepressants: A Real-World Systematic Observational Study in Psychiatric Settings. <i>PLoS ONE</i> , 2016, 11, e0155234.	1.1	5
66	Treating major depressive episodes with antidepressants can induce or worsen metabolic syndrome: results of the METADAP cohort. <i>World Psychiatry</i> , 2015, 14, 366-367.	4.8	42
67	Translational Research: Precision Medicine, Personalized Medicine, Targeted Therapies: Marketing or Science?. <i>Therapie</i> , 2015, 70, 11-19.	0.6	9
68	High metabolic N $\alpha$ -oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19* <i>17</i> genotype. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 782-784.	1.1	6
69	Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors. <i>Journal of Neural Transmission</i> , 2015, 122, 35-42.	1.4	27
70	<i>BDNF/TRKB/P75NTR</i> polymorphisms and their consequences on antidepressant efficacy in depressed patients. <i>Pharmacogenomics</i> , 2015, 16, 997-1013.	0.6	41
71	Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients. <i>Journal of Affective Disorders</i> , 2015, 175, 233-240.	2.0	44
72	Tobacco Consumption Concerns With the Use of CYP1A2 Metabolized Antidepressants. <i>American Journal of Psychiatry</i> , 2015, 172, 909-910.	4.0	3

#	ARTICLE	IF	CITATIONS
73	Menopausal status could modulate the association between 5-HTTLPR and antidepressant efficacy in depressed women: a pilot study. <i>Archives of Women's Mental Health</i> , 2014, 17, 569-573.	1.2	7
74	Serotonin Toxicity in a CYP2D6 Poor Metabolizer, Initially Diagnosed As a Drug-Resistant Major Depression. <i>American Journal of Psychiatry</i> , 2014, 171, 890-890.	4.0	9
75	The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 43-51.	0.7	42
76	Proton Pump Inhibitors Inhibit Methotrexate Transport by Renal Basolateral Organic Anion Transporter hOAT3. <i>Drug Metabolism and Disposition</i> , 2014, 42, 2041-2048.	1.7	49
77	Dependence of Efavirenz- and Rifampicin-Isoniazidâ€Based Antituberculosis Treatment Drug-Drug Interaction on CYP2B6 and NAT2 Genetic Polymorphisms: ANRS 12154 Study in Cambodia. <i>Journal of Infectious Diseases</i> , 2014, 209, 399-408.	1.9	45
78	Determination of the Most Influential Sources of Variability in Tacrolimus Trough Blood Concentrations in Adult Liver Transplant Recipients: A Bottom-Up Approach. <i>AAPS Journal</i> , 2014, 16, 379-391.	2.2	37
79	Cholesteryl Ester Transfer Protein Polymorphisms, Statin Use, and Their Impact on Cholesterol Levels and Cardiovascular Events. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 314-320.	2.3	12
80	P.2.b.026 Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients. <i>European Neuropsychopharmacology</i> , 2014, 24, S393.	0.3	1
81	Converging translational evidence for the involvement of the serotonin 2A receptor gene in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 54, 76-82.	2.5	44
82	P.3.005 BDNF Val66Met polymorphism predicts differential response to antidepressants in depressed Caucasian patients. <i>European Neuropsychopharmacology</i> , 2014, 24, S59-S60.	0.3	0
83	Tacrolimus dose requirement in pediatric liver transplantation: influence of <i>CYP3A5</i> gene polymorphism. <i>Pharmacogenomics</i> , 2013, 14, 1017-1025.	0.6	17
84	Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians. <i>Pharmacogenetics and Genomics</i> , 2012, 22, 868-876.	0.7	31
85	The Cytochrome P-450 2C9/2C19 but Not the ABCB1 Genetic Polymorphism May Be Associated With the Liver Cytochrome 3A4 Induction by Phenytoin. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 429-431.	0.7	1
86	Lack of Association of <i>OPRM1</i> and <i>ABCB1</i> Singleâ€Nucleotide Polymorphisms to Oxycodone Response in Postoperative Pain. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 234-242.	1.0	36
87	A Pharmacokineticâ€Pharmacodynamic Model for Predicting the Impact of CYP2C9 and VKORC1 Polymorphisms on Fluindione and Acenocoumarol During Induction Therapy. <i>Clinical Pharmacokinetics</i> , 2012, 51, 41-53.	1.6	26
88	Impact of genetic factors ( <i>VKORC1</i> , <i>CYP2C9</i> , <i>CYP4F2</i> and <i>EPHX1</i> ) on the anticoagulation response to fluindione. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 428-436.	1.1	14
89	Thyroid-stimulating hormone, 5-HTTLPR genotype, and antidepressant response in depressed women. <i>Psychiatric Genetics</i> , 2011, 21, 253-256.	0.6	5
90	Amoxicillin/clavulanic acidâ€warfarin drug interaction: a randomized controlled trial. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 232-236.	1.1	22

#	ARTICLE	IF	CITATIONS
91	Pharmacogenetics of Toxicity, Plasma Trough Concentration and Treatment Outcome with Nevirapine-Containing Regimen in Anti-Retroviral-Naïve HIV-Infected Adults: An Exploratory Study of the TRIANON ANRS 081 Trial. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2011, 109, 513-520.	1.2	19
92	Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction. <i>Circulation</i> , 2011, 123, 474-482.	1.6	140
93	The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the <i>OPRM1</i> and <i>ABCB1</i> genes. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 517-524.	1.0	92
94	Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients. <i>Current Opinion in Organ Transplantation</i> , 2010, 15, 601-607.	0.8	12
95	Antidepressants and ABCB1 Gene C3435T Functional Polymorphism: A Naturalistic Study. <i>Neuropsychobiology</i> , 2010, 62, 193-197.	0.9	30
96	Population Pharmacokinetic-Pharmacogenetic Study of Nevirapine in HIV-Infected Cambodian Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4432-4439.	1.4	38
97	<i>SLCO1B1</i> genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. <i>Pharmacogenomics</i> , 2010, 11, 1703-1713.	0.6	48
98	Human multidrug and toxin extrusion 1 ( <i>MATE1/SLC47A1</i> ) transporter: functional characterization, interaction with OCT2 ( <i>SLC22A2</i> ), and single nucleotide polymorphisms. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 298, F997-F1005.	1.3	122
99	Personalized medicine and antiplatelet therapy: ready for prime time?. <i>European Heart Journal</i> , 2009, 30, 1943-1963.	1.0	37
100	Gefitinib-phenytoin interaction is not correlated with the <sup>14</sup> C-erythromycin breath test in healthy male volunteers. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 226-237.	1.1	37
101	Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER Study. <i>Maturitas</i> , 2009, 64, 136-138.	1.0	0
102	Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. <i>New England Journal of Medicine</i> , 2009, 360, 363-375.	13.9	1,581
103	5-HTTLPR modulates antidepressant efficacy in depressed women. <i>Psychiatric Genetics</i> , 2009, 19, 195-200.	0.6	41
104	Influence of <i>CYP3A5</i> Genetic Polymorphism on Tacrolimus Daily Dose Requirements and Acute Rejection in Renal Graft Recipients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 103, 546-552.	1.2	102
105	Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 727-8.	1.0	10
106	Synergism between Oral Estrogen Therapy and Cytochrome P450 3A5*1 Allele on the Risk of Venous Thromboembolism among Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3082-3087.	1.8	31
107	Impact of VKORC1 Haplotypes on Long-Term Graft Function in Kidney Transplantation. <i>Transplantation</i> , 2008, 86, 779-783.	0.5	3
108	Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 437-449.	0.8	25

#	ARTICLE	IF	CITATIONS
109	Effects of type of smoking (pipe, cigars or cigarettes) on biological indices of tobacco exposure and toxicity. <i>Lung Cancer</i> , 2006, 54, 11-18.	0.9	44
110	Genetic Polymorphism of Vitamin K Epoxide Reductase (VKORC1) 1173C>T in a Chinese and a Caucasian Population. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 98, 611-613.	1.2	25
111	Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 200-209.	1.1	24
112	Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 449-460.	2.3	16
113	Environmental and genetic factors associated with morphine response in the postoperative period. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 316-324.	2.3	216
114	Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy. <i>Aids</i> , 2005, 19, 2127-2131.	1.0	37
115	Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. <i>Blood</i> , 2005, 106, 135-140.	0.6	335
116	Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 821-829.	0.8	47
117	Vitamin K epoxide reductase (VKORC1) genetic polymorphism is associated to oral anticoagulant overdose. <i>Thrombosis and Haemostasis</i> , 2005, 94, 690-691.	1.8	25
118	Cytochrome P450 2C9 (CYP2C9) Genotypes in a Nordic Population in Denmark. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2004, 94, 151-152.	1.2	10
119	Pharmacogenetics of acenocoumarol pharmacodynamics. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 403-414.	2.3	49
120	Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 73, 51-60.	2.3	75
121	Digoxin pharmacokinetics and MDR1 genetic polymorphisms. <i>European Journal of Clinical Pharmacology</i> , 2003, 58, 809-812.	0.8	149
122	Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. <i>Fundamental and Clinical Pharmacology</i> , 2003, 17, 373-376.	1.0	68
123	Association of the Multidrug Resistance-1 Gene Single-Nucleotide Polymorphisms with the Tacrolimus Dose Requirements in Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1889-1896.	3.0	257
124	Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. <i>Pharmacogenetics and Genomics</i> , 2001, 11, 735-737.	5.7	42